KORU Medical Systems Reports Strong 2025 Growth, Positive Adjusted EBITDA, and Optimistic 2026 Guidance

summarizeSummary

KORU Medical Systems announced robust 2025 financial results, including 22.2% revenue growth and a significant reduction in net loss, alongside a positive shift to adjusted EBITDA and optimistic 2026 guidance for continued growth and positive cash flow.

check_boxKey Events

• Strong 2025 Financial Performance

  Full year 2025 net revenues grew 22.2% to $41.1 million, with a 57% reduction in net loss to ($2.6) million.

• Shift to Positive Adjusted EBITDA

  The company achieved positive adjusted EBITDA of $0.6 million for the full year 2025, a 124% increase from the prior year.

• Optimistic 2026 Guidance

  KORU Medical initiated 2026 guidance projecting net revenue growth of 15-22% ($47.5 - $50.0 million), along with positive adjusted EBITDA and positive cash flow.

• Strategic Product & Pipeline Expansion

  Received 510(k) clearance for UCB RYSTIGGO®, achieved Freedom60® EU MDR certification, and announced two new pharmaceutical collaborations.

auto_awesomeAnalysis

This 8-K, furnishing the press release for the full year and fourth quarter 2025 results, signals a significant positive turning point for KORU Medical Systems. The company achieved strong revenue growth of 22.2% for the full year 2025 and substantially reduced its net loss by 57%. Critically, KORU Medical transitioned to positive adjusted EBITDA and projects positive cash flow for the full year 2026, indicating improved financial health and a clearer path to sustainable profitability. Additionally, strategic product developments, including 510(k) clearance for UCB RYSTIGGO® and new pharmaceutical collaborations, broaden the company's market reach and future growth opportunities. Investors should view these results and guidance as a strong indicator of operational execution and future potential.